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Cellular mechanisms of WNK4-
mediated regulation of ion 
transport proteins in the distal 
tubule
J-B Peng1 and PD Bell1
Gene mutations in WNK4 kinase cause a genetic form of hypertension 
by affecting multiple ion transport pathways through different 
mechanisms. Cai et al. report that the inhibitory effect of WNK4 on the 
thiazide-sensitive sodium-chloride cotransporter occurs through the 
lysosomal degradation pathway in mammalian cells.
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WNK (with no lysine (K)) kinases form 
a novel serine/threonine protein kinase 
family characterized by the absence of 
a conserved lysine residue in the kinase 
domain.1 Mutations in the WNK1 and 
WNK4 genes, two members of a family 
of four, are linked to pseudohypoaldo-
steronism type II (PHA II; also known 
as familial hyperkalemic hypertension 
or Gordon’s syndrome; Online Mende-
lian Inheritance in Man #145260), an 
autosomal dominant disease.2 Increased 
expression of WNK1 caused by deletions 
in the fi rst intron of the WNK1 gene, and 
missense mutations in the WNK4 gene 
close to its two coiled-coil domains out-
side the kinase region, lead to the devel-
opment of PHA II.2 Common features of 
PHA II include hyperkalemia, hyperten-
sion, mild metabolic acidosis, low renin, 
and normal glomerular fi ltration rate; this 
condition is a mirror image of Gitelman’s 
syndrome, which is caused by loss of func-
tion in the thiazide-sensitive sodium-
chloride cotransporter (NCC; SLC12A3, 
also known as TSC). This is especially 
true for patients carrying mutations in 
the WNK4 gene, who exhibit marked 
hypercalciuria and sensitivity to thiazide 
diuretics.3 Th ese clinical features served 
as the rationale that led two groups4,5 to 
independently report that WNK4 inhibits 
NCC when expressed in Xenopus oocytes, 
and that some disease-causing mutations 
of WNK4 exhibit decreased ability to 
inhibit NCC.
In addition to NCC, WNK4 has also 
been shown to inhibit renal epithelial ion 
channels, including the renal outer medul-
lary potassium channel (ROMK)6 and the 
transient receptor potential cation chan-
nel, subfamily V, member 4 (TRPV4).7 
Interestingly, WNK4 enhances the epithe-
lial calcium channel TRPV5 (previously 
known as ECaC) (J-B Peng et al., J Am 
Soc Nephrol 2004; 15: 62A, abstr.), and it 
increases paracellular Cl– permeability,8,9 
most likely through phosphorylation 
of claudins.8 Most recently, it has been 
shown that WNK4 phosphorylates the 
STE20-related serine/threonine kinases 
SPAK and OSR110 and, in turn, regulates 
the cation-Cl– cotransporters NKCC1 and 
KCC211 (Figure 1).
Th e mechanism of WNK4-mediated 
regulation of renal transporters and 
channels appears to be multifaceted 
(Figure 1). In contrast to the phosphory-
lation of claudins,8 SPAK, and OSR1,10 
WNK4 regulates membrane transport-
ers and ion channels by aff ecting plasma 
membrane abundance, as in the case of 
NCC,4,5 ROMK,6 TRPV4,7 and TRPV5 
(J-B Peng et al., J Am Soc Nephrol 2004; 
15: 62A, abstr.). Obviously, the amount 
of surface expression of a transport pro-
tein is an important determinant of ion 
transport activity, especially with regard 
to constitutive activity of membrane 
transport proteins. Surface expression of 
ion transporters is determined by several 
steps: biosynthesis, processing, insertion 
in the plasma membrane, removal from 
the plasma membrane, and protein deg-
radation. In the case of ROMK, WNK4 
facilitates the retrieval of ROMK from 
the plasma membrane through a clath-
rin-dependent pathway.6 This process 
is actually independent of kinase activ-
ity of WNK4, as the kinase-dead mutant 
exhibits the same eff ect on ROMK as the 
wild-type WNK4. In contrast, kinase-
dead WNK4 does not aff ect NCC activ-
ity.5 However, the WNK4 tail containing 
222 amino acid residues without the 
kinase domain is capable of inhibiting 
NCC, which suggests that kinase activity 
is not required for the inhibitory eff ect 
of WNK4 on NCC.12 Nevertheless, the 
cellular mechanism by which WNK4 
decreases the membrane level of NCC 
has not been resolved.
To further understand the regulation of 
NCC expression by WNK4, Cai et al.13 
(this issue) examined the eff ect of WNK4 
on NCC using African green monkey 
kidney Cos-7 and mouse cortical col-
lecting duct M-1 cells. One advancement 
achieved in these studies was the use of 
a mammalian expression system that 
provided a more physiologically relevant 
model as compared with expression in 
Xenopus oocytes. Th e authors confi rmed 
that wild-type WNK4 reduces the surface 
level of NCC in both Cos-7 and M-1 cells. 
Quantitative analysis of surface NCC by 
biotinylation indicated that disease-caus-
ing mutants R1185C and E562K partially 
failed and completely failed, respectively, 
to reduce the surface expression of NCC. 
Both wild-type WNK4 and E562K 
mutants co-immunoprecipitate NCC, 
indicating that the lack of an effect of 
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E562K on WNK4 was not due to a loss of 
interaction. Th e authors next examined 
whether clathrin-mediated endocytosis 
of NCC was aff ected by WNK4 using co-
transfection of dynamin 2 and its domi-
nant-negative mutant K44A, which arrest 
clathrin-coated pits at the plasma mem-
brane. Interestingly, the surface level of 
NCC was not aff ected by either dynamin 
2 or the K44A mutant in the presence or 
absence of WNK4. Th erefore, the clath-
rin-dependent pathway does not appear 
to be involved in the eff ects of WNK4 
on NCC. Lastly, bafilomycin, a vacu-
olar proton pump inhibitor, which may 
disrupt the acidifi cation of lysosomes, 
dose-dependently diminished the inhibi-
tory eff ect of WNK4 on the steady-state 
level of NCC expression. Th us it is likely 
that WNK4 causes the degradation of 
NCC before it is inserted into the plasma 
membrane. Hence, Cai et al.13 provide 
evidence that the action of WNK4 on 
NCC is through facilitation of degrada-
tion of this protein but not through the 
clathrin-dependent endocytosis. Th is is in 
striking contrast to the action of WNK4 
on ROMK.6
Th e study by Cai et al.13 suggests a novel 
mechanism of WNK4-mediated regula-
tion of an ion transporter. It remains to 
be determined how WNK4 acts on the 
lysosomal pathway, and what type of 
interaction occurs between WNK4 and 
NCC in this process. Ellison and co-
workers reported that a 222-amino acid 
WNK4 carboxyl-terminal fragment could 
inhibit NCC.12 How the E562K mutation, 
which is upstream of the carboxyl termi-
nal, could aff ect the lysosomal pathway 
remains an issue to be investigated.
It is intriguing that WNK4 acts on 
diff erent membrane transport proteins 
through diff erent mechanisms. It is con-
ceivable that the eff ects of WNK4 depend, 
at least to some extent, on the specifi c 
regulatory mechanisms that govern the 
activity and distribution of individual 
transporters. For example, WNK4 regu-
lates ROMK through the clathrin-depen-
dent endocytosis pathway, as ROMK is 
constitutively regulated by this pathway 
in the absence of WNK4. On the other 
hand, as Cai et al. show,13 NCC is not sig-
nifi cantly aff ected by the clathrin-depen-
dent endocytosis pathway in the absence 
or presence of WNK4. WNK4 regulates 
NCC through the lysosomal pathway. 
Th is may also help to explain the results 
obtained in the Xenopus oocyte expres-
sion system, where NCC is negatively 
regulated by WNK4 whereas TRPV5 is 
positively regulated by the same kinase. 
Th ese opposite eff ects of WNK4 on NCC 
and TRPV5 are consistent with the well-
known inverse relationship between 
sodium and calcium transport in the dis-
tal tubule. Th is suggests that the nature of 
regulation by WNK4 is, at least in part, 
coded within the transport protein.
Lessons learned from Xenopus oocyte 
and mammalian cell experiments serve 
to help our understanding of the molec-
ular mechanism of PHA II (Figure 1). 
Th e increase in NCC plasma membrane 
expression that results from disease-caus-
ing WNK4 mutations as shown by Cai et 
al.13 as well as previous studies4,5,12 sup-
ports the idea that NCC regulation plays 
an important role in the pathogenesis of 
PHA II. Th e disease-causing mutants of 
WNK4 enhance NCC-mediated sodium 
chloride reabsorption and decrease 
ROMK-mediated potassium secretion, 
leading to volume expansion, hyperka-
lemia, and hypertension. In addition, 
it is worth noting that the paracellular 
pathway for ion transport is also aff ected 
by WNK4. Th e chloride-shunt hypoth-
esis proposed by Schambelan et al.14 has 
gained experimental support by the dem-
onstration that disease-causing mutants 
of WNK4 lead to an increase in chloride 
permeability in MDCK cells.8,9 Accord-
ing to this hypothesis, the increased 
chloride permeability in the distal tubule 
would decrease the electrical driving 
force for potassium and proton secre-














































Figure 1 | Connection between clinical manifestation of pseudohypoaldosteronism type II 
(PHA II) and WNK4 function. WNK4 has been shown to regulate certain ion transport proteins 
expressed in the kidney, as shown in the upper left. Among them, differential effects between 
wild-type WNK4 and its disease-causing mutants have been observed for sodium-chloride 
cotransporter (NCC), renal outer medullary potassium channel (ROMK), and paracellular chloride 
permeability, as shown in the lower panel. There are different cellular mechanisms of WNK4 
regulation of ion transport proteins (see text): NCC is inhibited by WNK4 through enhancement 
of its lysosomal degradation; ROMK is inhibited by enhancement of the clathrin-dependent 
endocytosis; and claudins are phosphorylated in the presence of WNK4.  Ion transport activity is 
indicated by the thickness of the lines; the magnitude of WNK4’s effect is indicated by the size of 
the plus and minus symbols. For simplicity, NCC and ROMK are shown in the same cell.
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Hypercalciuria is a feature of patients 
carrying the WNK4 Q562E mutation and 
is not present in patients carrying WNK1 
mutations. As disease-causing mutations 
of WNK4 enhance TRPV5 to an extent 
comparable to that of wild-type WNK4 
(J-B Peng et al., J Am Soc Nephrol 2004; 
15: 62A, abstr.), it may be that other fac-
tors come into play in the hypercalciuria 
seen in PHA II. Distal tubular calcium 
reabsorption is inversely related to sodium 
reabsorption, and therefore the increase 
in calcium excretion may be linked to the 
elevation in distal tubular sodium reab-
sorption. In addition, the transcellular 
epithelial calcium channels TRPV5 and 
TRPV6 are also inhibited by acidosis.
Finally, WNK1 is also a regulator of the 
ion transporters ENaC and ROMK, which 
may provide a basis for the role of WNK1 
in the molecular pathogenesis of PHA II. 
New lines of evidence indicate that WNK1 
and WNK4 are upstream of two STE20-
type kinases, SPAK and OSR1, that regulate 
members of the SLC12A family of elec-
troneutral cation-Cl– cotransporters.10,11 
Th us, identifying at a cellular and molecu-
lar level the diff erences between wild-type 
WNK4 and disease-causing mutants and 
their eff ects on transport protein activity 
and expression levels should provide fur-
ther insight into the mechanisms underly-
ing the pathogenesis of PHA II.
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Chronic kidney disease in the 
elderly: is it really a premise for 
overwhelming renal failure?
F Locatelli1 and P Pozzoni1
Increasingly, the majority of patients being diagnosed as affected by 
chronic kidney disease (CKD) are elderly. Nonetheless, only a rather 
small proportion of elderly CKD patients actually progress to end-stage 
renal disease, whereas many more die before this stage is reached, 
largely because of cardiovascular disease. This underscores the urgent 
need for cardiovascular prevention, even more importantly than for 
renoprotection, among elderly patients with CKD.
Kidney International (2006) 69, 2118–2120. doi:10.1038/sj.ki.5001547
Chronic kidney disease (CKD) is becom-
ing increasingly common. The United 
States Renal Data System has reliably 
estimated that the number of patients on 
maintenance dialysis in the United States 
will double over the next few years,1 and a 
relatively large number of newly diagnosed 
CKD patients every year (incident CKD 
patients) are elderly. In Europe, an epide-
miological survey of the Île-de-France area 
showed a striking age-related increase in 
the annual incidence of CKD (that is, the 
fi rst evidence of serum creatinine levels 
greater than 2 mg per dl in the course of 
1 year): the incidence rate among patients 
aged more than 75 years was almost seven 
times that of patients aged 20–39 years 
(619 versus 92 new cases per million 
population) and more than twice that of 
patients aged 40–59 years (619 versus 264 
new cases per million population).2 Th e 
increased incidence of CKD among the 
elderly translates into a similarly increased 
prevalence: the Th ird National Health and 
Nutrition Examination Survey (NHANES 
III) of a nationally representative sample of 
adults in the United States between 1988 
and 1994 found that 7.6% of the individu-
als aged 60–69 years, and 25.9% of those 
aged at least 75 years, had a glomerular 
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